Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
A legfontosabb adatok
- Ki végzi
- Poitiers University Hospital
- Hol
- Franciaország37 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 224 fő, tervezett
- Kezdés
- 2018. dec. 19.
- Várható befejezés
- 2029. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- inhaled Ambisome®
- inhaled placebo
- Itraconazole
- A regiszteradat frissítve
- 2025. február 20.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- All adult patients affected with Chronic Pulmonary Aspergillosis (CPA) "de novo" or in relapse (without any history of resistance to itraconazole) combining the following criteria are eligible:
- Patient with an Aspergillus bronchopulmonary infection, be it cavitary, fibrotic, necrotizing (SIA/Semi Invasive Aspergillosis) or nodular and documented by compatible thoracic CT-scan images
- Associated with one of the following criteria:; positive detection of anti-Aspergillus IgG and/or precipitating anti-aspergillus antibodies, according to the positivity threshold of the laboratory performing the technique,; positive direct examination of Aspergillus or positive culture, from bronchopulmonary samples (expectoration or endoscopic aspiration),; revealing aspergillar hyphae/filaments on histological samples
- Men or women age ≥ 18 years
- For the women of childbearing age: women having a negative serum pregnancy test, having a contraception highly effective and accepting to pursue it during at least the first 12 months of the study
- Patient legally free and not subject to any custody, guardianship, tutelage or subordination measures
- Participants must be affiliated to France's Health Care Regime (" Sécurité Sociale ")
- Free and informed consent signed by each participating patient
Ki nem vehet részt
- - Patient presenting a contraindication to itraconazole (including all contraindicated co-administrated medications as listed in the itraconazole SmPc, including notably medications with potential to prolong theQT interval)
- - Patient presenting a contraindication to voriconazole and posaconazole (including all contraindicated coadministrated medications as listed in the SmPc)
- - Patient having presented complications related to a previous treatment by nebulised LAmB
- - Patient received an oral (excepted oral Amphotericin B), parenteral or intra-cavity antifungal treatment within the last 2 months
- - Concomitant use of one or several of treatments contra-indicated with the experimental or non-experimental treatment
- - Chronic Pulmonary Aspergillosis with indication for surgical intervention within 6 months from the start
- - Threatening hemoptysis, with impossibility to defer surgical procedures (but patients contraindicated to surgery may be included after resolution of the hemoptysis)
- - History of hypersensitivity reaction to liposomal amphotericin B or to itraconazole or to any other constituent
- - Invasive pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
- - Tuberculosis or progressive non-tuberculous mycobacteria
- - Respiratory infection aggravating the underlying CPA (patient may be included after eradication of infection)
- - Severe renal failure (clearance <30 ml / min)
- - Hepatic failure with transaminase and alkaline phosphatase values > 5 times normal
- - Significant abnormality of the blood cell and platelet counts (at the discretion of the investigator)
- - Ventricular dysfunction such as congestive cardiac failure or history of congestive cardiac failure or patients with risk(s) factors of cardiac arrhythmia or symptomatic arrhythmia with a prolongation of the corrected QT interval > 450 msec in men and 470 msec in women or treated by medication known to prolong QT interval, or prolongation of the corrected QT interval > 450 msec in men and 470 msec in women
- - Women at age to procreate and not using highly effective contraception, pregnant or breastfeeding women
- - Patient affected with single aspergilloma
- - Intolerance to beta2-agonists
- - Notion of relapse with isolation of an Aspergillus resistant to itraconazole
- - Patients with Cystic Fibrosis
- - Immunocompromised patients
- - Patient refusing to participate
- - Protected majors in the meaning of the law, non affiliated persons or with no social security scheme, persons deprived of liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies
- - Patient in exclusion period following participation in another interventional study evaluating antifungals or medicines
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromised patients affected by Chronic Pulmonary Aspergillosis (single aspergilloma excluded).
A teljes eredeti leírásKevesebb
• Control arm: Itraconazole 200 mg x 2/day associated with inactive nebulised treatment twice a week during 24 weeks.
• Experimental arm: Itraconazole 200 mg x 2/day associated with nebulised LAmB, at 25 mg twice a week during 24 weeks.
Follow up duration for the patients will be 24 months (12 months minimum) after discontinuation of the treatment being studied.
A vizsgálat 2 csoportja
- Itraconazole & inhaled placeboPlacebo, összehasonlításként
Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
Kezelés: inhaled placebo és Itraconazole
- Itraconazole & inhaled Ambisome®A vizsgált kezelés
Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
Kezelés: inhaled Ambisome® és Itraconazole
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Therapeutic Efficacy Comparison of a Six-month Treatment by Itraconazole and Nebulised Ambisome® Versus Treatment by Itraconazole Alone in Non- or Mildly- Immunocompromised Patients with Chronic Pulmonary Aspergillosis: a Prospective, Randomized, Single Blind Study, (single Aspergilloma Excluded)
- A regiszteradat frissítve
- 2025. február 20.